Who are Carvedilol SR 64mg, QD's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CarVeDilol-SR (Slow Release), Arotinolol Hydrochloride, Beta Blockers Carvedilol Phosphate, Carvedilol CR, Comparator: carvedilol, Carvedilol alone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carvedilol-sr-64mg-qd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Carvedilol SR 64mg, QD — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Carvedilol SR 64mg, QD (Carvedilol SR 64mg, QD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-blocker with alpha-1 blocking activity. Area: Cardiovascular.

phase 3 Beta-blocker with alpha-1 blocking activity Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Carvedilol SR 64mg, QD (Carvedilol SR 64mg, QD) — Chong Kun Dang Pharmaceutical. Carvedilol SR is a non-selective beta-blocker with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Carvedilol SR 64mg, QD TARGET	Carvedilol SR 64mg, QD	Chong Kun Dang Pharmaceutical	phase 3	Beta-blocker with alpha-1 blocking activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
CarVeDilol-SR (Slow Release)	CarVeDilol-SR (Slow Release)	Seoul National University Bundang Hospital	marketed	Beta-blocker with alpha-1 blocking activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Arotinolol Hydrochloride	Arotinolol Hydrochloride	Sumitomo Pharma (Suzhou) Co., Ltd.	marketed	Alpha-beta blocker	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Beta Blockers Carvedilol Phosphate	Beta Blockers Carvedilol Phosphate	Seoul National University Hospital	marketed	Beta blocker (non-selective, with alpha-1 blocking activity)	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Carvedilol CR	Carvedilol CR	University of Florida	marketed	Non-selective beta-blocker with alpha-1 blocking activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Comparator: carvedilol	Comparator: carvedilol	Organon and Co	marketed	Beta-blocker with alpha-1 antagonist activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Carvedilol alone	Carvedilol alone	Taipei Veterans General Hospital, Taiwan	marketed	Beta-blocker with alpha-1 antagonist activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-blocker with alpha-1 blocking activity class)

Chong Kun Dang Pharmaceutical · 2 drugs in this class
GlaxoSmithKline · 1 drug in this class
Seoul National University Bundang Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Carvedilol SR 64mg, QD — Competitive Intelligence Brief. https://druglandscape.com/ci/carvedilol-sr-64mg-qd. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab